A Key Clinical Message
Multidisciplinary treatment enabled the patient with stage IVB
intrahepatic cholangiocarcinoma to achieve long-term survival although
specific side effects of pemigatinib (nail disorders, hyperphosphatemia,
and taste disorders) was appeared.
Keywords: pemigatinib, intrahepatic cholangiocarcinoma,
fibroblast growth factor receptor 2, comprehensive genomic profiling